TransCode Therapeutics, Inc. (NASDAQ: RNAZ) has entered into an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics, Inc., obtaining rights to develop three drug candidates: UIO-524, UIO-525, and UIO-526. The agreement includes all in-licensed and owned rights previously held by Unleash. As compensation, Unleash will receive a one-time payment of 1,136,364 shares of a new series of non-voting convertible preferred stock from TransCode. These shares are convertible into an equal number of common shares and represent approximately 6.8% of TransCode's common stock on a fully diluted basis.
The lead candidate acquired through this license, UIO-524, is described as a next-generation oncolytic adenovirus. It is engineered to selectively replicate within malignant cells and cancer-associated stroma while delivering a multi-cytokine immune-activating payload. This mechanism is designed to treat solid tumors, with an initial clinical focus on muscle-invasive bladder cancer. The addition of UIO-524 to TransCode's portfolio expands its oncology pipeline, which is anchored by its lead asset, TTX-MC138. TTX-MC138 is advancing toward a Phase 2a clinical trial and is focused on treating metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis.
This strategic licensing move has significant implications for the oncology therapeutic landscape. By incorporating UIO-524, TransCode diversifies its approach beyond its core RNA therapeutic platform, entering the oncolytic virus space. Oncolytic viruses represent a growing frontier in cancer treatment, designed to selectively infect and destroy cancer cells while stimulating a broader anti-tumor immune response. The specific targeting of muscle-invasive bladder cancer addresses a condition with high unmet medical need, where new treatment options could substantially impact patient outcomes.
For the biotechnology industry and investors, the transaction structure is notable. The use of a stock-based, royalty-free license minimizes upfront cash expenditure for TransCode while aligning the interests of Unleash with the long-term success of the drug candidates' development. The expansion of TransCode's pipeline may enhance its value proposition and competitive positioning within the immuno-oncology sector. The company's broader portfolio, which includes other first-in-class candidates designed to mobilize the immune system against cancer, can be explored further at https://www.transcodetherapeutics.com.
The news was disseminated via BioMedWire (BMW), a specialized communications platform within the Dynamic Brand Portfolio at IBN that focuses on biotechnology and life sciences sectors. BMW provides services including wire distribution, editorial syndication, and social media distribution to reach investors and the public. More information about this platform is available at https://www.BioMedWire.com. The full details of the press release can be accessed at https://ibn.fm/adAZA, and ongoing updates related to TransCode Therapeutics are available in the company's newsroom at https://ibn.fm/RNAZ.
The acquisition of these candidates underscores the ongoing consolidation and partnership trends in biopharma, where clinical-stage companies like TransCode seek to bolster their pipelines through strategic in-licensing. For patients, particularly those with solid tumors like muscle-invasive bladder cancer, the development of UIO-524 represents a potential future therapeutic avenue that combines direct oncolytic action with immune system activation, a dual mechanism that could improve efficacy over single-modality treatments. The progression of these candidates through development will be closely watched by the medical and investment communities as TransCode works to translate this licensed technology into clinical benefits.
